Preferred Label : Anti-CD47 Monoclonal Antibody SHR-1603;
NCIt definition : A monoclonal antibody targeting the human cell surface antigen CD47, with potential
phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47
monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks
the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory
protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated
signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This
induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which
is specifically expressed on the surface of tumor cells, to low-density lipoprotein
(LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage
activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47
signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated
killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein
(IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic
stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression
of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage
activation and protects cancer cells from phagocytosis, which allows cancer cells
to proliferate.;
Molecule name : SHR 1603; SHR-1603;
NCI Metathesaurus CUI : CL969337;
Origin ID : C160202;
UMLS CUI : C5205033;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
